Vesalius Biocapital Partners Sàrl
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Luxembourg, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia
Industries Focus
- Healthcare
- HealthTech
- Life Sciences
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Medtech
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Therapeutics
- eHealth
- mHealth
Investment Size:
3,000,000 to 10,000,000 USD
Investor Details Founded: 2007
Vesalius Biocapital Partners Sàrl is a Luxembourg-based venture capital firm specializing in European life sciences investments. Since its inception in 2007, the firm has raised over €260 million across three funds and contributed to the development of more than 30 companies. The team comprises seasoned life science professionals with backgrounds in healthcare industry, corporate finance, and strategy consulting, supporting companies through their growth cycle. Vesalius Biocapital III, launched in April 2017, announced a final close with €120 million in commitments in 2019. The fund targets later-stage European life science companies in drug development, medical devices, diagnostics, and digital health. The firm's investment strategy focuses on three areas: therapeutics, medical devices, and diagnostics. Vesalius Biocapital Partners plays the role of lead investor in the majority of its financing rounds and is actively involved in the development of its portfolio companies. The firm is based in Europe, allowing for easy interaction with management teams and a deep understanding of the European market. Vesalius Biocapital Partners invests in all stages of development and is open to relatively early-stage projects with sound proprietary technology, unique team skills, and a clear competitive edge based on solid data. The firm has contributed to the development of over 20 companies since its inception, with more than €150 million under management in two funds. Vesalius Biocapital Partners is committed to supporting innovative life science companies in Europe and plays an active role in their growth and success.
Requirements
- Sound proprietary technology
- Unique team skills
- Clear competitive edge based on solid data
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- CatalYm
- HepaRegeniX
- OncoDNA
- Topas Therapeutics
- Nutrium
- ENYO Pharma
- HepaRegeniX GmbH
- Catalym GmbH
- OncoDNA S.A.
- Topas Therapeutics GmbH
Mentioned In
-
$49.95
-
$39.95
-
$24.95
-
$19.95
-
$19.95
-
$245.00
Claim this Investor
Are you an official representative of Vesalius Biocapital Partners Sàrl?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim